200,000+ products from a single source!
sales@angenechem.com
128607-22-7 | Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-
CAS No: 128607-22-7 Catalog No: AG000Y8C MDL No:MFCD00871890
Product Description
Catalog Number:
AG000Y8C
Chemical Name:
Ethanol, 2-[4-[(1Z)-4-chloro-1,2-diphenyl-1-buten-1-yl]phenoxy]-
CAS Number:
128607-22-7
Molecular Formula:
C24H23ClO2
Molecular Weight:
378.8912
MDL Number:
MFCD00871890
IUPAC Name:
2-[4-[(Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy]ethanol
InChI:
InChI=1S/C24H23ClO2/c25-16-15-23(19-7-3-1-4-8-19)24(20-9-5-2-6-10-20)21-11-13-22(14-12-21)27-18-17-26/h1-14,26H,15-18H2/b24-23-
InChI Key:
LUMKNAVTFCDUIE-VHXPQNKSSA-N
SMILES:
ClCC/C(=C(\c1ccccc1)/c1ccc(cc1)OCCO)/c1ccccc1
UNII:
B0P231ILBK
Properties
Complexity:
441
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
0
Defined Bond Stereocenter Count:
1
Exact Mass:
378.139g/mol
Formal Charge:
0
Heavy Atom Count:
27
Hydrogen Bond Acceptor Count:
2
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
378.896g/mol
Monoisotopic Mass:
378.139g/mol
Rotatable Bond Count:
8
Topological Polar Surface Area:
29.5A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
6.5
Literature
| Title | Journal |
|---|---|
| Ospemifene metabolism in humans in vitro and in vivo: metabolite identification, quantitation, and CYP assignment of major hydroxylations. | Drug metabolism and drug interactions 20130101 |
| An update on selective estrogen receptor modulators for the prevention and treatment of osteoporosis. | Maturitas 20120301 |
| Ospemifene and 4-hydroxyospemifene effectively prevent and treat breast cancer in the MTag.Tg transgenic mouse model. | Menopause (New York, N.Y.) 20120101 |
| Liver X receptors as regulators of macrophage inflammatory and metabolic pathways. | Biochimica et biophysica acta 20110801 |
| Pharmacologic evaluation of ospemifene. | Expert opinion on drug metabolism & toxicology 20100601 |
| An innovative method to classify SERMs based on the dynamics of estrogen receptor transcriptional activity in living animals. | Molecular endocrinology (Baltimore, Md.) 20100401 |
| Selective estrogen receptor modulators decrease the production of interleukin-6 and interferon-gamma-inducible protein-10 by astrocytes exposed to inflammatory challenge in vitro. | Glia 20100101 |
| Ospemifene effectively treats vulvovaginal atrophy in postmenopausal women: results from a pivotal phase 3 study. | Menopause (New York, N.Y.) 20100101 |
| Endometrial safety: a key hurdle for selective estrogen receptor modulators in development. | Menopause (New York, N.Y.) 20100101 |
| Current and emerging pharmacologic therapies for the management of postmenopausal osteoporosis. | Journal of women's health (2002) 20091001 |
| Ospemifene use in postmenopausal women. | Expert opinion on investigational drugs 20090601 |
| Estrogen and the selective estrogen receptor modulator (SERM) protection against cell death in estrogen receptor alpha and beta expressing U2OS cells. | Molecular and cellular endocrinology 20080716 |
| Pharmacologic effects of ospemifene in rhesus macaques: a pilot study. | Basic & clinical pharmacology & toxicology 20080601 |
| Differential effects of selective oestrogen receptor modulators (SERMs) tamoxifen, ospemifene and raloxifene on human osteoclasts in vitro. | British journal of pharmacology 20070601 |
| The cardiovascular effects of selective estrogen receptor modulators. | Annals of the New York Academy of Sciences 20061201 |
| Effects of ospemifene and raloxifene on biochemical markers of bone turnover in postmenopausal women. | Journal of bone and mineral metabolism 20060101 |
| Ineffectiveness of American ginseng in the prevention of dimethylbenzanthracene-induced mammary tumors in mice. | Oncology research 20060101 |
| Ospemifene inhibits the growth of dimethylbenzanthracene-induced mammary tumors in Sencar mice. | The Journal of steroid biochemistry and molecular biology 20051101 |
| Effects of ospemifene and raloxifene on hormonal status, lipids, genital tract, and tolerability in postmenopausal women. | Menopause (New York, N.Y.) 20050301 |
| Selective estrogen receptor modulators inhibit growth and progression of premalignant lesions in a mouse model of ductal carcinoma in situ. | Breast cancer research : BCR 20050101 |
| Selective estrogen receptor modulators prevent neointima formation after vascular injury. | Molecular and cellular endocrinology 20041130 |
| Ospemifene Hormos. | Current opinion in investigational drugs (London, England : 2000) 20040401 |
| Effects of ospemifene, a novel SERM, on biochemical markers of bone turnover in healthy postmenopausal women. | Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology 20040301 |
| Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus. | The Journal of steroid biochemistry and molecular biology 20040201 |
| Effects of ospemifene, a novel SERM, on hormones, genital tract, climacteric symptoms, and quality of life in postmenopausal women: a double-blind, randomized trial. | Menopause (New York, N.Y.) 20030101 |
| Effects of ospemifene, a novel SERM, on vascular markers and function in healthy, postmenopausal women. | Menopause (New York, N.Y.) 20030101 |
| Effects of ospemifene (FC-1271a) on uterine endometrium, vaginal maturation index, and hormonal status in healthy postmenopausal women. | Maturitas 20021120 |
| In vitro and in vivo biologic effects of Ospemifene (FC-1271a) in breast cancer. | The Journal of steroid biochemistry and molecular biology 20010601 |
| Cone voltage and collision cell collision-induced dissociation study of triphenylethylenes of pharmaceutical interest. | Rapid communications in mass spectrometry : RCM 20010101 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.